ImmunityBio, Inc. IBRX

Latest FY: 2025 Healthcare Biotechnology
Market Price $8.19
Market Cap $8.58B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑668.3% YoY
$113.29M
3-Yr CAGR: 678.6%
Net Income ↑15.0% YoY
-$351.40M
Net Margin: -310.2%
Free Cash Flow ↑22.4% YoY
-$308.78M
FCF Yield: -3.60%
EPS (Diluted) ↑38.7% YoY
$-0.38
Basic: $-0.38
Return on Equity Efficiency
N/A
ROA: -70.0%
⚡ N/A due to negative equity (share buybacks or other)

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (IBRX)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2023: Revenue YoY (+159.2%) is identical to Gross Profit YoY (+159.2%). Verify the underlying Revenue and Gross Profit values for FY 2023 and FY 2022.
  • FY 2024: Revenue YoY (+2270.6%) is identical to Gross Profit YoY (+2270.6%). Verify the underlying Revenue and Gross Profit values for FY 2024 and FY 2023.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $0.0M $-29.1M $-120.8M $-1.47 0.00% $-38.6M $-45.2M
FY 2017 $0.0M +2.3% $-42.0M $-96.4M +20.2% $-1.20 +18.4% 0.00% $-48.8M $-83.6M -85.1%
FY 2018 $0.0M +4.4% $-55.7M $-96.2M +0.2% $-1.22 -1.7% 0.00% $-63.4M $-76.5M +8.5%
FY 2019 $0.0M -8.5% $-49.7M $-65.8M +31.6% $-0.70 +42.6% 0.00% $-61.4M $-65.5M +14.3%
FY 2020 $0.1M +158.1% $-64.4M $-92.4M -40.4% $-0.89 -27.1% 0.00% $-70.5M $-73.1M -11.5%
FY 2021 $0.9M +741.4% $-195.0M $-346.8M -275.4% $-0.89 0.0% 0.00% $-274.4M $-308.0M -321.4%
FY 2022 $0.2M -74.3% $0.2M $-416.6M -20.1% $-1.04 -16.9% 0.00% $-337.5M $-415.7M -35.0%
FY 2023 $0.6M +159.2% $0.6M $-583.2M -40.0% $-1.15 -10.6% 0.00% $-366.8M $-397.3M +4.4%
FY 2024 $14.7M +2,270.6% $14.7M $-413.6M +29.1% $-0.62 +46.1% 0.00% $-391.2M $-398.1M -0.2%
FY 2025 $113.3M +668.3% $52.4M $-351.4M +15.0% $-0.38 +38.7% 0.00% $-304.9M $-308.8M +22.4%
$

Valuation

Market Price $8.19
Market Cap $8.58B
Enterprise Value $8.49B
P/E Ratio N/A
P/B Ratio N/A
FCF Yield -3.60%
Dividend Yield N/A
Shares Outstanding 1,047,354,000
%

Profitability & Margins

Gross Margin 46.26%
Operating Margin -226.00%
Net Margin -310.18%
Return on Equity (ROE) N/A (Negative Equity)
Return on Assets (ROA) -70.01%
Asset Turnover 0.23x
Revenue 3-Yr CAGR 678.62%
🛡️

Financial Health & Liquidity

Current Ratio 5.10
Cash Ratio 1.43
Debt / Equity -0.000
Debt / Assets 0.000
Cash & Equivalents $88.33M
Total Debt N/A
Book Value / Share $-0.48
💧

Cash Flow Efficiency

Operating Cash Flow -$304.94M
Capital Expenditures (CapEx) $3.85M
Free Cash Flow -$308.78M
OCF / Revenue -269.17%
FCF / Revenue -272.56%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-0.38
EPS (Basic) $-0.38
Dividends / Share N/A
Book Value / Share $-0.48
EPS YoY Growth 38.71%
🏛️

Balance Sheet (FY 2025)

Total Assets $501.90M
Total Liabilities $1.00B
Stockholders' Equity -$500.47M
Current Assets $314.88M
Current Liabilities $61.75M